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 Abstract  
 
HPLC analysis of N-glycans quantified levels of the biantennary glycan (A2) in plasma 
proteins of 924 individuals. Subsequent genome-wide association study (GWAS) using 
317,503 single nucleotide polymorphysms (SNP) identified two genetic loci influencing 
variation in A2: FUT 8 and ESR2. We demonstrate that human glycans are amenable to 
GWAS and their genetic regulation shows sex-specific effects with FUT 8 variants explaining 
17.3% of the variance in pre-menopausal women, while ESR2 variants explained 6.0% of the 
variance in post-menopausal women. 
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Main text  
 
Glycosylation, which involves the addition of sugar chains to proteins and lipids, is the most 
complex and abundant post-translational modification (1). This process is not directly 
template driven and gives rise to the extensive complexity of the glycoproteome, estimated to 
be several orders of magnitude more complex than the proteome itself (2). In eukaryotes, 
glycosylation occurs through 11 biosynthetic pathways (3). One of these pathways is N-
glycosylation, which occurs when a block of 14 sugars (the dolichol phosphate precursor) is 
transferred co-translationally to specific Asn residues in newly synthesized polypeptides in 
the endoplasmic reticulum. The resulting N-glycans are subjected to extensive modification as 
the glycoproteins mature and move via the Golgi complex to their intra- and extra-cellular 
destinations (4).  
 
N-glycosylation is essential for multicellular life and its complete absence is embryonically 
lethal (5). Genetic defects that affect protein glycosylation through biosynthetic or 
degradation pathways are relevant to human health and are at the root of at least 30 human 
diseases (2,6). A surprisingly high proportion of disease-causing mis-sense mutations result in 
gains of glycosylation sites (7,8). Population variability in terminal glycans is also common 
(e.g., ABO blood groups) and contributes to the protein heterogeneity that can be 
advantageous for evading pathogens and adapting to a changing environments (9). However, 
due to experimental limitations in quantifying glycans in complex biological samples, 
understanding of the genetic regulation of glycosylation is still very limited (2). 
 
Until recently, detailed quantitative analysis of total plasma glycans was generally performed 
on a limited number of samples due to the technological challenges (10). However, using a 
newly developed 96 well plate platform we have demonstrated that human plasma N-glycans 
can be separated into chromatographic peaks and reliably quantified using high-performance 
liquid chromatography (HPLC) (11,12). This represents a major technological advance, which 
was required to investigate the genetic regulation and biological role of glycan structures and 
for bringing glycomics into line with genomics, proteomics and metabolomics. We analysed 
the distribution of plasma glycans in a sample of 924 individuals recruited as part of a larger 
study of several hundred disease-related quantitative traits in a Croatian isolated population 
(12,13). Firstly, we found unusual biological variability at the population level with the 
median ratio of minimal to maximal values of 6.2 (from data on 33 chromatographic classes 
of N glycans (12)) and significant age- and gender-specific effects were also present. 
Heritability estimates for individual glycans varied widely, ranging from very low to very 
high. Environmental determinants were also detected, including diet and smoking (12).  
 
In parallel to these developments in high-throughput glycome analysis, high-throughput 
genome analysis has brought unprecedented successes in gene identification in recent years 
(14). Genome-wide association studies are now established as a reliable and powerful tool to 
identify genetic variants underlying biological variation in quantitative traits and complex 
human diseases (15). This paper represents the first attempt to investigate whether a GWAS 
approach can be applied to the study of genetic regulation of individual glycan in human 
plasma quantified by HPLC. 
  
In the HPLC method, only one glycan structure (A2, GlcNAc2Man3GlcNAc2) was 
individually quantified, while all others were clustered into groups that share similar 
structures and require further enzymatic treatment to separate them (12). Glycan A2 mostly 
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originates from immunoglobulin G (IgG) and differences in glycans attached to IgG 
glycoforms potentially affect disease susceptibility through effects on immune function 
(16,17). Glycan A2 showed substantial heritability in our study sample of 924 individuals 
residing in Croatian island isolates (h2=0.48; SE(h2) = 0.11). After initial HPLC 
quantification of glycan A2 we performed sialidase digestion to improve measurement 
precision. Trait concentrations were then log10-transformed, standardized by sex and age and 
z-transformed prior to genetic analysis. We successfully performed a genome-wide 
association study using 317,503 single nucleotide polymorphisms (SNPs) in 924 individuals 
from the Croatian isolate (12). An association was considered statistically significant at the 
genome-wide level if the p-value for an individual SNP was less that 1.7x10-7 (based on 
Bonferroni correction to account for multiple testing). For details of the methods used see 
Supplementary Methods. 
 
The genome-wide association study identified a “peak” on chromosome 14 (Figure 1), which 
included 6 single nucleotide polymorphisms (SNPs) showing association with glycan A2 and 
genome-wide significance. The most significant association was found with single nucleotide 
polymorphism rs7161123 located in intron 2 of the gene fucosyltransferase 8 (FUT8) (p=1.09 
x 10-8). This implies that fucosyltransferase 8 is the key regulator of glycan A2 concentration 
in human plasma. Allele A of this SNP alone explained 3.93% of the variance of glycan A2 
(after adjustment for age and sex). This association is highly biologically plausible because 
glycan A2 is a known substrate for FUT8 (18). In addition to FUT8, there are three other 
enzymes that are directly involved in the metabolism of A2 glycan and which could 
potentially affect its plasma concentration (18): (i) α-1,6-mannosyl-glycoprotein 2-β-N-
acetylglucosaminyltransferase, an enzyme that adds N-acetylglucosamine to mannoses and 
creates glycan A2; (ii) β-1,4-mannosyl-glycoprotein β1,4- N-acetylglucosaminyltransferase 
III, an enzyme that adds bisecting N-acetylglucosamine  and decreases A2 by converting it to 
A2B; (iii) β-1,4-galactosyltransferase 1, an enzyme that adds galactose to N-
acetylglucosamines and converts glycan A2 to A2G and A2G2 structures. We were not able 
to identify any SNPs in the genes encoding those enzymes that significantly affect glycan A2 
concentrations in our study sample. 
 
More detailed analyses provided further insights into the genetic regulation of glycan A2. In a 
genome-wide association study of glycan A2 levels prior to desialylation (sialidase digestion) 
of all glycans the peak on chromosome 14 was still apparent, but it barely reached genome-
wide statistical significance. This implies that sialidase digestion improved the detectability of 
true genetic effects on a N-glycan and should be performed prior to HILIC HPLC analysis in 
genetic association studies. In addition, it was noted that the entire peak on Chr 14 can be 
explained by independent effects of only 2 SNPs: rs7161123 (in gene FUT8) and rs3020450, 
which also showed a strong association with glycan A2 (p=6.56 x 10-6) (Table 1). The latter 
SNP is located in a different gene (estrogen receptor beta - ESR2) and acts independently and 
additively with FUT8 to regulate levels of glycan A2. The independence between the action 
of two SNPs is illustrated by physical separation of the peaks on chromosome 14 on a higher 
resolution (r2 = 4.68x10-04) (Supplementary figure 1) and the p-value for the effect of the 
interaction of the two SNPs on A2 glycan level was not statistically significant.  Analysis of 
the combined effects of rs7161123 in FUT8 and rs3020450 in ESR2 on glycan A2 levels 
through multi-locus analysis showed p-value of 1.36 x 10-12 for the association of the 
haplotype with the trait in an additive model, with a combined effect of the two SNPs on the 
variance of glycan A2 (adjusted for age and sex) of 6.66%. This increased to 10.84% when 
the analysis was performed separately in females and decreased to 2.67% when performed 
only in males (Supplementary table 1). 
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Further analyses provided novel insights into the nature of genetic regulation of N-glycans in 
human plasma. A separate genome-wide association study by gender was performed, in which 
the values of glycan A2 were adjusted for age only. In this study conducted in 536 females 
rs7161123 in FUT8 was again the SNP most significantly associated with glycan A2 (p=1.15 
x 10-9). An analysis in 388 males did not show any significant associations with glycan A2. 
The effect size of rs7161123 allele A in FUT8 in females was large, explaining 7.59% of age-
adjusted trait variance (in comparison to 0.57% in males only). A similar study of rs3020450 
in the ESR2 gene (A allele tested) showed the effect of SNP on the variance of the trait of 
2.73% (3.25% in females and 2.10% in males). Thus, the association with FUT8 appears to be 
restricted to females, while ESR2 affects glycan A2 in both sexes.  
 
The breakdown of females into premenopausal (N=166) and postmenopausal groups (N=352) 
and further association analysis showed that FUT8 rs7161123 explains 17.31% of the trait 
variance (adjusted for age) in premenopausal women and 3.61% in postmenopausal women. 
In contrast, ESR2 rs3020450 explained 0.51% of A2 glycan in premenopausal and 5.96% in 
postmenopausal women. 
 
This is the first study of human N-glycan concentrations, measured as a quantitative trait, 
using a genome-wide association study. Recent technological advances in high-throughput 
glycome analyses combined with high-throughput genomics and mass spectrometry of 
proteins and lipids are set to reveal complex interactions between genes, proteins, lipids and 
glycans and unknown steps in metabolic pathways. This first insight into genetic regulation of 
plasma levels of an individual glycan (A2) showed strong sex-specific effects, differences in 
pre- and post-menopausal life and multi-locus effects, similar to many other quantitatively 
varying biological traits (19,20). It also showed that desialylation of glycan A2 before HPLC 
analysis reduced the measurement “noise” and so increased the power of the study to detect 
genetic effects. Although glycosylation is the most complex and abundant posttranslational 
modification, the importance of complex oligosaccharide structures attached to proteins for 
human health is only beginning to be appreciated (17). This is not surprising, since 
sequencing or synthesizing of branched sugar structures is significantly more challenging than 
the analysis of linear DNA and protein sequences (11). However, this study is encouraging 
because it shows that these difficulties can be overcome. In the next few years, we should 
expect new and exciting discoveries on the role of glycan structures in human biology, health 
and disease.  
 
 
Supplementary Methods 
 
Human samples. This study was based on samples from respondents who were residents of 
the Croatian island of Vis and who were recruited within a larger genetic epidemiology 
program which seeks to investigate genetic variability influencing common complex diseases 
and disease-related traits in genetically isolated populations (21). The island of Vis is one of 
the Dalmatian islands that has been moderately isolated throughout history. The sampling 
framework was based on the voting register which was used to send postal invitations to all 
adult inhabitants (over 18 years of age). The sample for this study consisted of a total of 1008 
individuals aged 18-93 years (median age 56, interquartile range 24 years). There were 415 
men (41.2%) and 593 women (58.8%). Genealogical records were reconstructed based on the 
Church Parish records and information provided by the respondents, and then checked against 
genetic data on allele sharing between relatives as a quality control measure to exclude data 
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errors. The sample contained a total of 809 genealogical relationships (including 205 parent-
child, 123 sibling, and 481 other relationships). Blood samples were centrifuged at the time of 
collection and EDTA plasma aliquots stored at -70 °C until analysis. This study conformed to 
the ethical guidelines of the 1975 Declaration of Helsinki. All respondents signed informed 
consent before participating in the study and the study was approved by the appropriate Ethics 
Board of the University of Zagreb Medical School.  
 
Glycan release and labeling. The N-glycans from plasma sample (5 μl) proteins were 
released and labeled with 2-aminobenzamide (LudgerTag 2-AB labeling kit Ludger Ltd., 
Abingdon, UK) as described previously (22). Labeled glycans were dried in a vacuum 
centrifuge and redissolved in known volume of water for further analysis.  
 
Sialidase digestion. Aliquots of the 2-AB-labeled glycan pool were dried down in 200-μl 
microcentrifuge tubes. To these, the following was added: 1 μl of 500 mM sodium acetate 
incubation buffer (pH 5.5), 1 μl (0.005 units) of ABS, Arthrobacter ureafaciens sialidase 
(releases α2–3, 6, 8 sialic acid, Prozyme) and H2O to make up to 10 μl. This was incubated 
overnight (16–18 h) at 37 °C and then passed through a Micropure-EZ enzyme remover 
(Millipore, Billerica, MA, USA) before applying to the HPLC. 
 
Hydrophilic interaction high performance liquid chromatography (HILIC). Released 
glycans were subjected to hydrophilic interaction high performance liquid chromatography 
(HILIC) on a 250 x 4.6 mm i.d. 5μm particle packed TSKgel Amide 80 column (Anachem, 
Luton, UK) at 30°C with 50 mM formic acid adjusted to pH 4.4 with ammonia solution as 
solvent A and acetonitrile as solvent B. 60 min runs were on a 2795 Alliance separations 
module (Waters, Milford, MA). HPLCs were equipped with a Waters temperature control 
module and a Waters 2475 fluorescence detector set with excitation and emission 
wavelengths of 330 and 420 nm, respectively. The system was calibrated using an external 
standard of hydrolyzed and 2-AB-labeled glucose oligomers from which the retention times 
for the individual glycans were converted to glucose units (GU) (23). Glycans were analyzed 
on the basis of their elution positions and measured in glucose units then compared to 
reference values in the “GlycoBase” database (available at: http:// glycobase.nibrt.ie) for 
structure assignment (24).  
 . 
Genotyping. A genome-wide association scan using 317,503 SNPs (Human Hap300, 
Illumina) was initially carried out in 991 Croatian individuals and scored using the 
BeadStudio software v.3 (Illumina). We removed a total of 7,096 SNPs that had <95% 
genotyping call rates, 1,289 that had a minor allele frequency <2% 113 that were out of 
Hardy-Weinburg equilibrium (p<1 x 10-10) and 9 X-linked markers that were likely to be 
autosomal, leaving 308,996 SNPs in the analyses. 
 
Genome-wide association analysis. We removed 60 individuals who had low call rates 
(<97%), one individual with too high IBS (a known twin) and 6 individuals with sex 
discrepancies, leaving 924 individuals in this analysis. Genome-wide associations between 
glycan A2 phenotype and single nucleotide polymorphic (SNP) markers were analysed using 
the “mmscore” function of the GenABEL package for R statistical software 
(http://mga.bionet.nsc.ru/nlru/GenABEL), using an additive model. This score test for family 
based association (25) takes into account pedigree structure and allowed unbiased estimations 
of SNP allelic effect relatedness between examinees. The relationship matrix used in this 
analysis was generated by the “ibs” function of GenABEL which used IBS genotype sharing 
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to determine the realised pairwise kinship coefficient similarly to the PLINK “genome” 
function. All identified SNPs that reached significance or seemed to be suggestive of 
significance were visualised using HaploView software 
(http://www.broad.mit.edu/mpg/haploview/).  The percentage of the variance explained by 
one or 2 SNPs was calculated using the “polygenic” function of the “GenABEL” package. 
Haplotype analysis was performed using the haplo.stat package for R (http://cran.r-
project.org/web/packages/haplo.stats/index.html). 
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Table 1: A list of single nucleotide polymorphysms (SNPs) that showed association with 
glycan A2 reaching statistical significance of p<10-5 in genome-wide association studies that 
included all examinees, females only and males only. Chromosome (chr) and position of each 
SNP, alleles found in studied sample, effective alleles (and their frequency in studied sample), 
size of the observed effect on glycan A2 (with 95% confidence intervals), p-value of 
significance of association with glycan A2 and implicated genes are shown for each SNP.  
 
 
SNP Chr Position Alleles 
Effective 
Alleles 
Eff. Allele 
Frequency Effect Size
95% CI (Effect Size) 
P-Value Genes In Region Lower Upper 
ALL EXAMINEES INCLUDED (N=924) 
rs6560442 9 77104027 G/A A 0.0910 0.3180 0.1745 0.4615 9.31E-06 no genes +/- 100kb 
rs8006145 14 63769203 C/A A 0.2549 -0.1852 -0.2648 -0.1055 3.35E-06 ESR2 
rs3020450 14 63838055 G/A A 0.3072 -0.1539 -0.2223 -0.0856 6.56E-06 ESR2 
rs7159888 14 64828395 G/A A 0.4323 0.1243 0.0710 0.1777 3.10E-06 no genes +/- 100kb 
rs11621121 14 64892246 A/G G 0.4431 0.1380 0.0867 0.1893 7.44E-08 55kb 5' FUT8 
rs2411822 14 64948148 A/G G 0.4602 -0.1355 -0.1849 -0.0861 4.19E-08 FUT8 
rs1953416 14 64948560 G/A A 0.4566 -0.1289 -0.1788 -0.0789 2.52E-07 FUT8 
rs7161123 14 65122654 G/A A 0.4806 -0.1369 -0.1847 -0.0891 1.03E-08 FUT8 
rs743085 14 65137886 A/G G 0.4824 -0.1348 -0.1822 -0.0873 1.34E-08 FUT8 
rs2411351 14 65241294 A/G G 0.4851 -0.1329 -0.1802 -0.0857 1.84E-08 FUT8 
rs10483785 14 65289270 G/A A 0.4903 -0.1270 -0.1735 -0.0806 4.55E-08 10kb 3’ FUT8 
FEMALES ONLY INCLUDED (N=536) 
rs4852139 2 240475479 G/A A 0.2758 -0.2150 -0.3120 -0.1180 9.34E-06 predicted gene region
rs11621121 14 64892246 A/G G 0.4375 0.1886 0.1182 0.2590 8.31E-08 55kb 5' FUT8 
rs8013442 14 64941614 G/A A 0.3489 0.1895 0.1053 0.2737 6.80E-06 6kb 5' FUT8 
rs2411822 14 64948148 A/G G 0.4688 -0.1889 -0.2552 -0.1227 1.16E-08 FUT8 
rs1953416 14 64948560 G/A A 0.4686 -0.1790 -0.2449 -0.1131 5.57E-08 FUT8 
rs1959144 14 65015804 C/A A 0.3499 0.1905 0.1060 0.2750 6.50E-06 FUT8 
rs4902399 14 65026650 G/A A 0.3503 0.1918 0.1071 0.2764 5.85E-06 FUT8 
rs3783711 14 65098199 G/A A 0.3470 0.1873 0.1028 0.2718 9.24E-06 FUT8 
rs7161123 14 65122654 G/A A 0.4844 -0.1956 -0.2599 -0.1314 1.12E-09 FUT8 
rs743085 14 65137886 A/G G 0.4864 -0.1920 -0.2559 -0.1282 1.82E-09 FUT8 
rs7144971 14 65190403 A/G G 0.3426 0.1983 0.1120 0.2847 4.34E-06 FUT8 
rs2411351 14 65241294 A/G G 0.4892 -0.1825 -0.2456 -0.1194 7.30E-09 FUT8 
rs10483785 14 65289270 G/A A 0.4942 -0.1747 -0.2369 -0.1125 1.93E-08 10kb 3’ FUT8 
MALES ONLY INCLUDED (N=388) 
No SNPs reached genome-wide significance of p<10-5 
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Supplementary table 1: Analysis of the effects of haplotypes involving rs7161123 in FUT8 
and rs3020450 in ESR2 in genome-wide association studies involving all examinees, males 
only and females only. P-values represent the statistical significance of association of 
haplotype with glycan A2 under additive model of the effects of two SNPs. Var. expl. denotes 
proportion of explained variance in measured levels of glycan A2 in the study sample. 
 
 
Allele Haplotype 
rs7161123 rs3020450 Frequency Score P-Value 
All examinees (N=924; p=1.356 x 10-12; Var. expl.=6.66%) 
A A 0.15228 -6.86666 6.57E-12 
A G 0.32830 -1.58025 0.1141 
G A 0.15489 -0.15728 0.8750 
G G 0.36452 6.46952 9.83E-11 
Females only (N=536; p=1.547 x 10-11; Var. expl.=10.84%) 
A A 0.14859 -6.1794 6.435E-10 
A G 0.33579 -2.62385 0.00869 
G A 0.15453 0.26854 0.78829 
G G 0.3611 6.4874 8.733E-11 
Males only (N=388; p=0.00519; Var. expl.=2.67%) 
A A 0.15736 -3.51292 0.00044 
A G 0.15548 -0.39137 0.69552 
G A 0.31790 0.53437 0.59308 
G G 0.36926 2.37867 0.01738 
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Figure 1. The result of genome-wide association study for N-linked A2 glycan 
(GlcNAc2Man3GlcNAc2) in human plasma of 986 individuals from Vis island, Croatia. 
HPLC analysis of fluorescently-labelled N-glycan A2 was followed by sialidase digestion and 
standardization by sex and age, which all increased detectability of underlying genetic 
variants. There is a clear “peak” at chromosome 14 including 6 single nucleotide 
polymorphysms showing association with A2 glycan beyond genome-wide significance level 
after Bonferroni correction (P =1.7x10-7) represented by red horizontal line.  
 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.2
86
4.
1 
: P
os
te
d 
10
 F
eb
 2
00
9
 
 
Supplementary figure 1. The independence between the action of rs7161123 in FUT8 and 
rs3020450 in ESR2 on glycan A2 levels is shown by physical separation of the peaks on 
chromosome 14 on a higher resolution. Correlation (r2) between the two SNPs is only 
4.68x10-04. Analysis of the combined effects of rs7161123 in FUT8 and rs3020450 in ESR2 
on glycan A2 levels shows strong haplotype effects and explains up to 10% of the trait 
variance. 
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